International workshop on immune tolerance induction: consensus recommendations.
Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of scientific evidence to guide therapeutic decision-making. In an effort to provide direction for physicians and hemophilia treatment center staff members, an international panel of hemophilia opinion leaders met to develop consensus recommendations for ITI in patients with severe and mild hemophilia A and hemophilia B. These recommendations draw on the available published literature and the collective clinical experience of the group and are rated based on the level of supporting evidence.
DiMichele
D M
DM
Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA. dmdimich@med.cornell.edu
Hoots
W K
WK
Pipe
S W
SW
Rivard
G E
GE
Santagostino
E
E
D019774:Blood Coagulation Factor Inhibitors / Q000276:immunology*; D002408:Catheters, Indwelling; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D004868:Equipment Failure; D005164:Factor IX / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000493:pharmacokinetics; D005169:Factor VIII / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000493:pharmacokinetics; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007223:Infant; D007239:Infections / Q000150:complications / Q000276:immunology; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D017211:Treatment Failure
D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII; D005164:Factor IX